Medytox disclosed on the 12th that operating profit on a consolidation basis last year was 17.2 billion won, down 15% from a year earlier. Revenue for the same period rose 8% to 247.3 billion won.
The company said operating profit and net profit fell from a year earlier due to higher selling and administrative expenses and the impact of business restructuring, including the winding down of subsidiaries.
However, as sales of botulinum toxin products increased, total revenue hit an all-time high for the third consecutive year.
By product, sales of "Coretox" increased in the domestic premium toxin market, and the next-generation toxin product "NEWLUX" expanded its overseas footprint along with domestic sales. As a result, toxin institutional sector revenue grew 25% from a year earlier.
Filler institutional sector revenue fell 5% from a year earlier. However, the company launched two new products in the "Neuramis" series and unveiled new advertising for the "Neuramis" and "Attiere" brands as it moved to address domestic and overseas markets.
Medytox plans to push for the launch this year of the submental fat reduction injection "NewVisu." "NewVisu" is a product approved by the Ministery of Food and Drug Safety as the 40th domestically developed new drug.
Along with this, it will also push to expand its health functional food business using the probiotic "MT961," which has a body fat reduction function. The strain has been recognized by the Ministery of Food and Drug Safety as an individually approved functional ingredient.
A Medytox official said, "We expect the new products scheduled for launch in the first half to positively impact mid- to long-term results," and added, "We will continue to enhance our competitiveness in the global aesthetics market based on ongoing research and development and diversification of our product portfolio."